QRG Capital Management Inc. Buys 3,616 Shares of Zoetis Inc. $ZTS

Key Points

• QRG Capital Management Inc. increased its stake in Zoetis Inc. by 4.9%, acquiring an additional 3,616 shares, bringing its total holdings to 77,741 shares worth approximately $12.12 million.
• Zoetis reported a strong quarterly performance with $1.76 EPS, exceeding analysts' expectations, and a revenue of $2.46 billion, marking a 4.2% increase from the previous year.
• Analysts have set a consensus target price of $200.88 for Zoetis, with ratings varying between a "buy" and "hold" by different brokerages.

QRG Capital Management Inc. lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,741 shares of the company's stock after acquiring an additional 3,616 shares during the period. QRG Capital Management Inc.'s holdings in Zoetis were worth $12,124,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Sound Income Strategies LLC increased its position in Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company's stock valued at $67,000 after buying an additional 152 shares in the last quarter. Portside Wealth Group LLC increased its position in Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after buying an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. increased its position in Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after buying an additional 198,089 shares in the last quarter. Soros Capital Management LLC increased its position in Zoetis by 32.0% during the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company's stock valued at $2,872,000 after buying an additional 4,230 shares in the last quarter. Finally, Flagship Harbor Advisors LLC increased its position in Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after buying an additional 1,760 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.0%

Shares of ZTS opened at $146.45 on Friday. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. The stock's 50-day moving average price is $149.79 and its 200-day moving average price is $155.08.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the business earned $1.56 earnings per share. The company's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZTS. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.